DelveInsight’s “Opioid Use Disorder Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Opioid Use Disorder, historical and forecasted epidemiology as well as the Opioid Use Disorder market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Discover Key Insights into the Opioid Use Disorder Market with DelveInsight’s In-Depth Report @ Opioid Use Disorder Market Size
Key Takeaways from the Opioid Use Disorder Market Report
Stay ahead in the Opioid Use Disorder Therapeutics Market with DelveInsight’s Strategic Report @ Opioid Use Disorder Market Outlook
Opioid Use Disorder Epidemiology Segmentation in the 7MM
Download the report to understand which factors are driving Opioid Use Disorder epidemiology trends @ Opioid Use Disorder Prevalence
Opioid Use Disorder Marketed Drugs
BRIXADI contains buprenorphine, a partial opioid agonist. It is prescribed for moderate to severe opioid addiction in individuals who have initiated treatment with buprenorphine or are already undergoing buprenorphine therapy. It’s an integral part of a comprehensive treatment plan that includes counseling and behavioral therapy.
BRIXADI is approved in both weekly and monthly subcutaneous injectable formulations at varying doses, including lower doses that may be appropriate for those who do not tolerate higher doses of extended-release buprenorphine that are currently available. The weekly doses are 8 milligrams (mg), 16 mg, 24 mg, 32 mg; and the monthly doses are 64 mg, 96 mg, and 128 mg.
SUBLOCADE, a partial opioid agonist, and is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine‐containing product, followed by dose adjustment for a minimum of 7 days. SUBLOCADE should be part of a complete treatment program that includes counseling and psychosocial support.
Opioid Use Disorder Emerging Drugs
BXCL501 is an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine, a selective alpha-2a receptor agonist for the treatment of agitation and opioid withdrawal symptoms. BioXcel believes that BXCL501 potentially targets a causal agitation mechanism, and the company has observed anti-agitation results in multiple clinical studies across several neuropsychiatric disorders. The drug is in Phase Ib/II trial assessing safety, pharmacokinetics, tolerability, and efficacy by administering it twice daily for seven days to patients with opioid withdrawal symptoms.
Get In-Depth Knowledge on Opioid Use Disorder Market Trends and Forecasts with DelveInsight @ Opioid Use Disorder Treatment Market
Opioid Use Disorder Therapies and Companies
Opioid Use Disorder Treatment Market
Although effective therapies are available, only about 1 in 4 patients with opioid use disorder (OUD) receives specialized care. Medication for opioid use disorder (MOUD), considered the “gold standard” of treatment, is an evidence-based approach for managing OUD. While counseling and behavioral therapies are important components of treatment, they are not effective on their own. Medications help treat cravings, alleviate withdrawal symptoms, and prevent opioid euphoria. These medications do not “cure” the disorder but increase safety and minimize withdrawal symptoms, which can lead to relapse or continued drug use. The three FDA-approved medications commonly used for OUD treatment are methadone, buprenorphine, and naltrexone.
Opioid Use Disorder Market Dynamics
The Opioid Use Disorder market dynamics are expected to change significantly in the coming years. Following the United States’ recognition and response to its opioid crisis, there has been increased awareness and funding for OUD research and development. Although only a few active compounds have proven effective in treating OUD, their various and innovative formulations have significantly enhanced treatment adherence and reduced relapses. The elimination of the DATA 2000 waiver and the cap on the number of patients a physician can treat with buprenorphine is expected to further transform the OUD market landscape in the US, expanding the use of buprenorphine in treatment. Additionally, upcoming policy reforms are projected to improve patient access to medication for opioid use disorder (MOUD) and its utilization in therapy
Unlock Strategic Insights with DelveInsight’s Comprehensive Opioid Use Disorder Market Report @ Opioid Use Disorder Market Drivers and Barriers
Scope of the Opioid Use Disorder Market Report
Table of Content
1 Key Insights
2 Report Introduction
3 Opioid Use Disorder (OUD) Market Overview at a Glance
4 Executive Summary of Opioid Use Disorder
5 Key Events
6 Disease Background and Overview
7 Treatment and Management
8 Methodology
9 Epidemiology and Patient Population
10 Patient Journey
11 Marketed Drugs
12 Emerging Drugs
13 Opioid Use Disorder (OUD): Seven Major Market Analysis
14 KOL Views
15 SWOT Analysis
16 Unmet needs
17 Market Access and Reimbursement
18 Appendix
19 DelveInsight Capabilities
20 Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage
